Evaluation of malnutrition status and clinical indications in children with celiac disease: a cross-sectional study

Zahra Setavand 1, Maryam Ekramzadeh 2* and Naser Honar 3

Abstract

Background: Celiac Disease (CD) is an autoimmune systemic disorder triggered by gluten in genetically susceptible individuals, which can lead to chronic malabsorption. Considering the changes in the manifestations of CD, this study aimed to determine anthropometric indices and clinical indications in children with CD.

Methods: This cross-sectional study aimed to evaluate the children with CD who had referred to Imam Reza Celiac Clinic between 2016 and 2019. Totally, 361 children were eligible and their anti-tissue transglutaminase (TGA-IgA) level, weight, height, and Body Mass Index (BMI) were extracted from their records. The anthropometric indices were presented based on the criteria of the Center for Disease Control and Prevention (CDC) and World Health Organization (WHO). The prevalent symptoms were assessed, as well.

Results: Based on the CDC’s criteria, 18.3, 28.8, and 25.8% of the children had short stature, low body weight, and low BMI, respectively. These measures were obtained as 10, 22.4, and 13.9% according to the WHO’s categorization respectively. Furthermore, the most common symptoms among the children were abdominal pain (56.5%), skeletal pain (27.4%), constipation (25.8%), and anemia (23.8%).

Conclusion: To sum up, the results clearly indicated that growth failure and low height, weight, and BMI were prevalent among the children with CD. Moreover, in addition to gastrointestinal symptoms, a considerable number of patients had skeletal pain and anemia.

Keywords: Celiac disease, Children, Stature, Body weight, BMI, Gluten, Growth

Background

Celiac Disease (CD) is known as a chronic autoimmune enteropathy triggered by storage protein of wheat, barley, and rye called gluten, which has been reported to have a wide range of clinical features [1, 2]. CD is a multifactorial disorder affected by the interaction between gluten ingestion and immune response as well as environmental and genetic factors [3]. Worldwide assessments have demonstrated that CD affected almost 1 % of the European population [4]. Based on serological evaluations in Iran, the prevalence of CD was reported 1 out of 167 children [5]. However, the prevalence of CD has been found to be higher in a variety of diseases, such as Irritable Bowel Syndrome (IBS), diabetes, and neurological disorders (11, 12, and 3.7%, respectively) [6]. Formerly, CD was only considered in patients with obvious malabsorption and Gastrointestinal (GI) manifestations, including abdominal distension, abdominal pain, chronic diarrhea, constipation, nausea, and vomiting [7–9]. Nowadays, however, there is no sign of classical symptoms in many patients and extra-intestinal symptoms, such as growth failure, dental enamel defect, and iron-deficiency anemia, have become dominant.

* Correspondence: mekramzade@gmail.com
2Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
In fact, the clinical symptoms of CD go beyond GI presentations [9]. According to the Oslo classification of CD, different types of classic, non-classic, subclinical, potential, and refractory has been identified [10, 11]. The classic CD is characterized by signs and symptoms of malabsorption and the non-classic one presents with extra-intestinal symptoms. The subclinical CD is below the threshold of clinical detection. In potential CD, the patients at risk of developing the disease are recognized [12]. Mucosal damage of the proximal part of the intestine and fat malabsorption cause nutrients, vitamins (D, K, and B9), and minerals (iron and zinc) deficiency, which can in turn increase the risk of hypocalcemia, rickets, osteoporosis, coagulation disorders, anemia, and malnutrition [13–16]. In addition to nutrients malabsorption, reduced food intake is associated with poor growth in pediatric patients with CD [17]. Furthermore, decrease in Insulin Growth Factor-1 (IGF-1) and Growth Hormone (GH) levels may be correlated to their impaired nutritional status. These pathways lead to various extra-intestinal manifestations of CD, such as short stature, growth retardation, and delayed puberty, which should be taken into account when dealing with children suffering from CD [15, 18]. Considering the data regarding the increasing trend in the incidence of CD [19], evaluation, diagnosis, and management of its clinical symptoms are essential.

Since CD has a heterogeneous spectrum of symptoms, proper growth of children is of paramount importance. Considering the lack of data regarding malnutrition, growth pattern, and dominant clinical nutrition related symptoms in the Iranian pediatrics with CD, the present study aims to investigate the anthropometric features and clinical manifestations of children with CD. The information extracted from this study will enable us to ameliorate CD-related complications in the future studies.

Methods

Study design

The present cross-sectional study was a part of a retrospective cohort assay conducted on patients with CD. The participants were selected from the patients with medical records referred to Imam Reza specialized nutrition and diet therapy clinic for CD affiliated to Shiraz University of Medical Sciences, Shiraz, Iran from September 2016 to September 2019. Mucosal atrophy at the biopsies was described by an expert pathologist. Then CD diagnosis confirmed by a gastroenterologist based on biopsy results and anti-tissue transglutaminase (TGA-IgA). The inclusion criteria were age between 2 and 18 years, positive diagnosis of CD by a specialist, and completed relevant forms about the personal information and clinical signs of CD. Patients with other chronic disorders [renal diseases, cirrhosis, malignancies, and organ failures] were excluded.

The study was approved by the Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.REC.1398.1153). Entirely, the medical records of 361 patients were reviewed and included in the analysis. The patients were assured about the confidentiality of their information.

Participants’ characteristics

The researchers extracted the participants’ demographic and anthropometric information from data records. Data including age, time of diagnosis, anti-tissue transglutaminase (TGA-IgA), related comorbidities [Type 1 Diabetes Mellitus (DMT1), Hashimoto thyroiditis etc], clinical symptoms, weight, height, and Body Mass Index (BMI) were collected after diagnosis and at their first visit to specialized nutrition and diet therapy clinic. Height was measured by a stadiometer to the nearest 0.1 cm without shoes. Weight was also measured by a calibrated scale (Omron, Korea) with an accuracy of 0.1 kg [20]. Anthropometric indices, including weight, height, and BMI (weight (kg)/height (m²)) [21], were presented based on the criteria of the Center for Disease Control and Prevention (CDC) and World Health Organization (WHO). Based on the CDC criteria for stature and weight for age, values less than the 5th percentile, between the 5th and the 95th percentiles, and higher than the 95th percentile were categorized as unfavorable, normal, and high, respectively. In addition, BMI values < the 5th percentile, between the 5th and the 85th percentiles, and ≥ the 95th percentile were categorized as underweight, normal weight, and overweight and obese, respectively [22].

Considering the WHO’s references, height and weight values < −2 z-score, between −2 to +2, and ≥ +2 were categorized as low, sufficient, and high, respectively. In addition, z-scores < −3, −3 ≤ −2, −2 ≤ −1, 1 ≤ −2, and ≥ 2 for BMI indicated severe thinness, thinness, normal status, overweight, and obesity, respectively [23].

Clinical manifestations assessment

A questionnaire was used to assess the prevalent symptoms among the children with CD, including diarrhea, flatulence, abdominal pain, abdominal distention, constipation, skeletal pain (including both osteopenia related pain at legs and arthralgia induced by autoimmune disease), hair loss, skin dryness, weight loss, diabetes, hypothyroidism, anemia, lactose intolerance, and nausea.

Statistical analysis

All analyses were performed using the SPSS software, version 21 (SPSS Inc., Chicago, IL, USA). The normality of the data was assessed using Kolmogorov-Smirnov test. Frequency and percentage were reported to describe the qualitative variables and mean and Standard Deviation (SD) were used for quantitative variables. Mann–
Whitney and Kruskal-Wallis tests were used to assess the effect of disease duration on anthropometric indices. \( P < 0.05 \) was considered statistically significant.

**Results**

**Participants**
The study results indicated that out of the 361 subjects, 63.7\% (\( n = 230 \)) were female. The mean age of the patients was 9.55 ± 3.72 years, and there was no significant difference between the females (9.35 ± 0.32) and males (9.89 ± 3.73) with respect to age.

Sixty-two participants (17.2\%) had Type 1 Diabetes Mellitus (T1DM) and 29 ones (8\%) had hypothyroidism. Demographic and anthropometric data of the children with celiac disease are summarized in Table 1.

**Height for age values in the children with CD**

According to the results presented in Table 2, based on the CDC percentiles of height for age, 66, 290, and 5 patients have short, normal, and tall, respectively. However, considering the categorization of WHO z-scores, 36, 324, and 1 patients had low, normal, and high values of height for age, respectively.

**Weight for age values in the children with CD**

Based on the results presented in Tables 3, 104, 252, and 5 patients were in the low, normal, and high percentiles of weight for age, respectively. In addition, the z-scores of weight for age were lower than –2 in 81 children, between –2 and +2 in 276, and higher than +2 in four children.

**Table 1 Demographic and anthropometric data of the children with celiac disease**

| Variable             | Range                | Celiac patients |
|----------------------|----------------------|-----------------|
| Age                  | 2–18                 | 9.55 ± 3.72 [9.16–9.93] \(^a\) |
| Age at diagnosis     | 1–17.33              | 8.00 (5.00) [7.84–8.55] |
| TGA-IgA (U/ml)       | 0.9–972              | 59.80 (114.75) [98.04–142.80] |
| Height (cm)          | 79–180               | 130.12 ± 20.51 [128.00–132.25] |
| Weight (kg)          | 8.10–103.30          | 25.10 (17.85) [26.97–29.70] |
| BMI (kg/m\(^2\))     | 11.23–38.41          | 15.08 (3.28) [15.52–16.12] |
| Height percentile    | < 0–98               | 22.00 (41) [27.95–35.52] |
| Weight percentile    | < 0–99               | 13.00 (34) [20.66–25.94] |
| BMI percentile       | < 0–99               | 19.00 (44) [25.11–30.79] |
| Height z-score       | −5.18 – 2.02         | −0.75 ± 1.11 [−0.87 – −0.64] |
| Weight z-score       | −4.73 – 2.29         | −1.12 ± 1.21 [−1.25 – −0.99] |
| BMI z-score          | −6.25 – 2.19         | −0.96 ± 1.28 [−1.09 – −0.83] |

BMI body mass index, TGA-IgA anti-tissue transglutaminase

\(^a\)Continuous data with normal distribution are expressed as means ± SDs (95\% confidence interval) and continuous data with skewed distribution as median (IQR) (95\% confidence interval)

\(^b\)TGA-IgA levels higher than 100 U/ml as an indicator of the CD diagnosis

**BMI for age values in the children with CD**

Evaluation of BMI based on the criteria of CDC and WHO has been shown in Table 4. According to the percentiles, 93, 252, 10, and 6 patients were considered underweight, normal, overweight, and obese, respectively. Furthermore, the z-scores of BMI were less than –3 in 21 children and more than +2 in only three children. Almost 76\% of the patients had normal BMI for age based on WHO’s categorization.

**The prevalence of malnutrition in the children with CD**

The prevalence of malnutrition, including stunting (low height for age), underweight (low weight for age), overweight, and obesity, among the children was evaluated according to WHO’s definitions. However, wasting could not be assessed due to its definition (low weight for height in less than 10-year-old children) and the participants’ wide age variation [24]. Based on the results, 10, 22.4, 3.9, and 0.8\% of the patients suffered from stunting, underweight, overweight, and obesity, respectively.

**The effect of the disease duration on height, weight, and BMI**

We considered the time span between the age of diagnosis of celiac disease by gastroenterologist and the first visit to specialized nutrition and diet therapy clinic as disease duration. Our aim was to assess the effect of the disease duration on height, weight, and BMI. The results revealed no significant difference among the participants with short, normal, and tall statures concerning the duration of the disease (\( p = 0.97 \) for CDC and \( p = 0.98 \) for WHO). The results also indicated no significant difference among the underweight, normal, and overweight individuals with respect to the duration of the disease (\( p = 0.61 \) for CDC and \( p = 0.64 \) for WHO). There was also no significant difference with regard to BMI according to the criteria of CDC (\( p = 0.95 \)) and WHO (\( p = 0.48 \)) (Table 5).

**Clinical manifestations in the children with CD**

Common symptoms of CD among the children have been summarized in Table 6. Accordingly, the most common problems among the patients were abdominal pain (56.5\%), skeletal pain (28\%), constipation (27.4\%), and anemia (23.8\%). Furthermore, 16.3\% of the participants had the experience of weight loss. Other GI manifestations, such as diarrhea (15\%), flatulence (15\%), lactose intolerance (10.8\%), and nausea (3.6\%), were also present.

**Discussion**

The present cross-sectional study provided information about weight, height, BMI, malnutrition prevalence, and clinical features related to CD in pediatrics. Considering malnutrition status, most of the children with celiac
disease were in the normal range and a small proportion of them were malnourished. Based on the CDC’s criteria, 18.3, 28.8, and 25.8% of the participants had short stature, low body weight, and low BMI for age, respectively. In addition, according to the WHO’s criteria, 10% of the patients had short stature for age and 22.4% had low body weight for age, while almost 5.8% were severely thin based on BMI for age. However, few people were overweight and obese, which was unpredictable in people with CD. Furthermore, abdominal pain, skeletal pain, constipation, and anemia were the most common clinical symptoms amongst the children with CD.

In the last few decades, the clinical features of CD have changed remarkably. The classic picture of CD is shrinking, while asymptomatic or with few symptoms, forms of CD have become dominant [25]. Nowadays, growth failure and short stature have been reported as the most common extra-intestinal features of CD, originating from the malabsorption syndrome [17, 26]. Although the exact mechanism of short stature is not obvious, nutrient deficiency, resistance to GH, and low level of IGF-1 have been proposed for growth retardation in children suffering from CD [27]. In some children, the only manifestation of CD is impaired growth, which makes the disease diagnosis difficult [28]. Moreover, there is an evidence that CD can affect children’s stature and cause growth retardation beyond GH deficiency [17]. According to the results of the present research, 18.3 and 10% of the children had short stature based on the criteria of CDC and WHO, respectively. Similar results were also obtained in some other studies. For instance, Giovenale et al. evaluated 7066 children with short stature at the age of 2–14 years and came to the conclusion that 44 children (0.63%) had CD [29]. In addition, Assiri performed a study on children in Saudi Arabia and indicated that 10.9% of those with short stature had CD, while 4.3% of them were suspicious to have CD [18]. In the same line, Jaweria Masood et al. assessed 300 children with short stature and demonstrated that 120 ones suffered from CD [30]. Farooq et al. also disclosed that 12% of the children with atypical CD had short stature and 30% had anemia together with short stature [31].

The results of the current study showed that approximately 20–30% of the children with CD were malnourished in terms of low body weight and low BMI for age. Intestinal mucosal damage in CD leads to non-optimal weight gain and malnutrition due to malabsorption of such nutrients as glucose, fatty acids, calcium, iron, vitamins, and electrolytes [32, 33]. In addition, due to impaired nutrients absorption in patients with CD, carbohydrates oxidize more to provide energy [33]. Bardella et al. maintained that weight, BMI, lean mass, and fat mass were significantly lower in patients with CD compared to the controls [34]. Furthermore, Barera et al. indicated that the patients with untreated CD had lower fat mass and body weight compared to their matched participants in the control group [35]. Moreover, Dehbozorgi et al. indicated that 31 and 29% of the children with CD suffered from low body weight and low BMI for age, respectively [4]. In the present study, approximately 1–5% of the patients were overweight and obese based on both WHO and CDC’s criteria. Although it has been assumed that patients with CD are likely to be underweight, some evidence has suggested that these patients were increasingly overweight or obese at the time of diagnosis (8–40%) in western countries, and that CD could coexist with obesity in both children and adults [29–31]. The results of the study by Calcaterra demonstrated that among 200 overweight and obese children, 4% of them suffered from CD [36]. Nenna et al. also reported that among 1527 overweight/obese children and adolescents, 11.1% were positive for celiac disease [37]. Another study in Saudi pediatric population showed that in 119 cases diagnosed with CD, 48% had normal growth or were overweight/

### Table 2
The frequency distribution of height for age in the children with celiac disease according to the criteria of CDC and WHO

| Height for age | CDC’s criteria (percentile) N (%) | WHO’s criteria (z-score) N (%) |
|---------------|---------------------------------|------------------------------|
| Short stature | < 5                             | 66 (18.3)                    |
| Normal stature | 5–95                           | 290 (80.3)                   |
| Tall stature  | ≥ 95                            | 5 (1.4)                      |

**CDC center for disease control and prevention, WHO world health organization**

### Table 3
The frequency distribution of weight for age in the children with celiac disease according to the criteria of CDC and WHO

| Weight for age | CDC’s criteria (percentile) N (%) | WHO’s criteria (z-score) N (%) |
|---------------|---------------------------------|------------------------------|
| Underweight   | < 5%                            | 104 (28.8)                   |
| Normal weight | 5 _ 95%                         | 252 (69.8)                   |
| Overweight    | ≥ 95%                           | 5 (1.4)                      |

**CDC centers for disease control and prevention, WHO world health organization**
obese [38]. Singh et al. indicated in their study that 21 out of the 210 cases (9.1%) were overweight and obese [39]. Additionally, Valletta et al. showed that 3% of the children with CD were obese and had z-scores higher than +2 [40]. According to a compensatory hypothesis, nutrients absorption might increase by preserved intestinal cells after a while and lead to excess energy intake [41]. Hence, celiac patients with normal or increased body weight should not be excluded at the diagnosis stage.

In the current study, the most common clinical symptoms were abdominal pain, skeletal pain, constipation, and anemia. Diabetes and hypothyroidism were also prevalent as comorbidities in these patients. The previous reports focused on GI symptoms, especially diarrhea, in CD. The present study findings indicated that 15% of the patients had diarrhea as a comorbidity. However, atypical CD that presents with extra-intestinal features in the absence of diarrhea is now predominant [42]. A study by Ehsani-Ardakan et al. indicated that the majority of the patients with CD (range: 1–87 years) had diarrhea, dyspepsia, and constipation. Based on non-GI presentation, however, anemia and osteopenia were the most prevalent symptoms [43]. Reilly et al. also stated that growth problems, abdominal pain, autoimmune thyroid disease, and T1DM were prevalent in the children with CD [44]. Based on the results of a recent meta-analysis, the worldwide prevalence of CD varied from 0.7 to 1.4% [45], and T1DM was associated with a high risk of CD and increased the risk of CD by up to 20 folds [46]. Some studies have claimed that early exposure to gluten might increase the risk of both CD and T1DM [47–49]. Additionally, Sategna-Guidetti et al. evaluated 241 untreated adults with CD and showed the three-fold higher prevalence of thyroid disease among the patients. Besides, 12.9% of the patients were diagnosed with hypothyroidism [50]. As the subclinical type of CD in the context of autoimmune diseases has become more prevalent [51], early and proper evaluation of these patients is of paramount importance.

TGA-IgA and duration of CD are two probable factors related to the disease severity. Different studies on pediatrics have shown TGA-IgA level as a predictor of villous atrophy [52, 53] and TGA-IgA levels higher than 100 U/mL as an indicator of the CD diagnosis [54]. In this context, Singh et al. found that increased mucosal abnormality was accompanied by an increase in the TGA-IgA level [55]. In addition, celiac manifestations could be parallel with organ-specific autoimmunity in long term and age at diagnosis is the only remarkable predictor of developing an additional autoimmune disease [56]. Duration of exposure to gluten has also been reported to play a critical role in development of CD. Ventura et al. demonstrated that gluten exposure increased the risk of other autoimmune complications in CD [57]. Also evidence has shown that various indices

**Table 4** The frequency distribution of BMI for age in the children with celiac disease according to the criteria of CDC and WHO

| CDC’ s criteria (percentile) | N (%) | WHO’s criteria (z-score) | N (%) |
|-----------------------------|-------|-------------------------|-------|
| < −3                        | 21 (5.8) | Severe thinness         |       |
| −3 < −2                     | 50 (13.9) | Thinness                |       |
| −2 < −1                     | 273 (75.6) | Normal                 |       |
| −1 < 0                      | 14 (3.9) | Overweight              |       |
| ≥ 0                         | 3 (0.8) | Obese                   |       |

**Table 5** Comparison of disease duration regarding height, weight, and BMI based on the criteria of CDC and WHO

| Variables based on the CDC’s criteria | Duration (years) Mean ± SD | P-value | Variables based on the WHO’s criteria | Duration (years) Mean ± SD | P-value |
|--------------------------------------|---------------------------|---------|--------------------------------------|---------------------------|---------|
| Height                               |                           |         |                                      |                           |         |
| Short                                | 1.34 ± 2.25               | 0.97    | Short                                | 1.60 ± 2.69               | 0.98    |
| Normal                               | 1.36 ± 2.13               |         | Normal                               | 1.32 ± 2.07               |         |
| Tall                                 | 0.83 ± 1.32               |         | Tall                                 | 0.00 ± 0.00               |         |
| Weight                               |                           |         |                                      |                           |         |
| Underweight                          | 1.41 ± 2.22               | 0.61    | Underweight                          | 1.40 ± 2.27               | 0.64    |
| Normal                               | 1.33 ± 2.12               |         | Normal                               | 1.33 ± 2.11               |         |
| Overweight                           | 1.15 ± 1.68               |         | Overweight                           | 1.43 ± 1.79               |         |
| BMI                                  |                           |         |                                      |                           |         |
| Underweight                          | 1.13 ± 1.74               | 0.95    | Severe thinness                      | 1.37 ± 2.17               | 0.48    |
| Normal                               | 1.44 ± 2.31               |         | Thinness                             | 1.03 ± 1.75               |         |
| Overweight                           | 1.12 ± 1.31               |         | Normal                               | 1.41 ± 2.25               |         |
| Obese                                | 1.16 ± 1.50               |         | Overweight and obese                 | 1.18 ± 1.31               |         |

CDC center for disease control and prevention, WHO world health organization; BMI, body mass index
including disease duration, the number of diabetes auto-
antibodies, and the adherence to GFD seems to affect
the trend of CD related autoimmune response after GFD
regimen [58]. However, the present study results re-
vealed no significant relationships between the disease
duration and anthropometric indices. In the same vein,
Seyhan et al. indicated no significant relationships be-
 tween the cutaneous results and the disease duration.
However, mucosal findings were more severe in the pa-
 tients with longer CD durations [59].

Limitations: One of the strong points of the present in-
vestigation was the expression of anthropometric data
based on both CDC and WHO’s criteria. However, the
main limitation of this research was the lack of data about
the patients’ dietary intakes, which impeded the investiga-
tion of the relationship between anthropometric indices
dietary factors. Another study limitation was the lack
of information about the serum levels of growth hormone
and insulin. If body composition and Bone Mineral Den-
 sity (BMD) were assessed by Dual-Energy X-ray Absorpti-
ometry (DEXA) method and serum levels of nutritional
indices like serum albumin, prealbumin, vitamin D,
calcium, phosphorus, and iron were assessed, the inter-
pretation of malnutrition and evaluation of growth failure
would be easier. Another limitation of this study was
the lack of a control group. Finally, since the study was
conducted on a wide age category, weight for height as a
good index for assessing malnutrition could not be evaluated.

Conclusion
This study clearly showed that CD could affect the growth
rate of the children in terms of height and weight. Al-
though the common presentation of classic CD in
pediatrics is growth retardation, some cases of overweight
and obesity were detected in this population. In addition
to GI symptoms, including abdominal pain and constipa-
tion, such extra-intestinal features as skeletal pain and
anemia were prevalent, as well. Considering the ascending
trend of CD incidence, appropriate nutritional evaluation
of these patients is essential in early ages for proper
diagnosis and management. Moreover, future studies are
required to apply solutions to reduce CD-related
complications.

Table 6 The frequency distribution of the clinical symptoms
observed in the children with celiac disease

| Clinical symptoms          | N (%) | Clinical symptoms          | N (%) |
|----------------------------|-------|----------------------------|-------|
| Diarrhea                   | 54 (15)| Skin dryness               | 54 (15)|
| Flatulence                 | 54 (15)| Weight Loss                | 59 (16.3)|
| Abdominal pain             | 204 (56.5)| Nausea                   | 13 (3.6)|
| Abdominal distention       | 5 (1.4)| Hair loss                  | 35 (9.7)|
| Constipation               | 99 (27.4)| Anemia                   | 86 (23.8)|
| Skeletal pain              | 101 (28)| Lactose intolerance       | 39 (10.8)|

Abbreviations
CD: Celiac disease; BMI: Body mass index; CDC: Center for disease control
and prevention; WHO: World health organization; GI: Gastrointestinal;
IBS: Irritable bowel syndrome; IGF-1: Insulin growth factor-1; GH: Growth
hormone; TGA-IgA: Anti-tissue transglutaminase; SD: Standard deviation;
T1DM: Type 1 diabetes mellitus; BMD: Bone mineral density; DEXA: Dual-
energy X-ray absorptiometry

Acknowledgments
The authors would like to appreciate Miss S. Saboori at the Research
Consultation Center (RCC) of Shiraz University of Medical Sciences for
statistical consulting. They are also grateful for Ms. A. Keivanekhouch at the
Research Improvement Center of Shiraz University of Medical Sciences
for improving the use of English in the manuscript.

Authors’ contributions
ZS: design, data gathering, data analysis, and preparing the manuscript.
NH: data gathering and preparing the manuscript. ME: concept, design, data
analysis, and preparing the manuscript. All authors have read and approved
the manuscript.

Funding
This manuscript was extracted from an MSc thesis written by Zahra Setavand
and financially supported by Shiraz University of Medical Sciences.

Availability of data and materials
The datasets used and/or analyzed during the current study is available from
the corresponding author upon request.

Declarations
Ethics approval and consent to participate
This study was approved by the Ethics Committee of Shiraz University of
Medical Sciences (IR.SUMS.REC.1398.1153). All methods in the present study
were performed in accordance with the principles of the relevant guidelines
and regulations of Declaration of Helsinki, which is a statement of ethical
principles that directs physicians and other participants in medical research
involving human subjects. Informed consent was also obtained from the
parents/legal guardians of the patients involved in the study after explaining
the aim, method, and goal of the research.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Student Research Committee, Shiraz University of Medical Sciences, Shiraz,
Iran. 2Nutrition Research Center, Department of Clinical Nutrition, School of
Nurition and Food Sciences, Shiraz University of Medical Sciences, Shiraz,
Iran. 3Neonatal Research Center, Shiraz University of Medical Sciences, Shiraz,
Iran.

Received: 9 January 2021 Accepted: 22 March 2021
Published online: 29 March 2021

References
1. Mearin ML. Celiac disease among children and adolescents. Curr Problems
Pediatr Adolesc Health Care. 2007;37(3):86–105. https://doi.org/10.1016/j.
peds.2007.01.001.
2. Fasano A, Catassi C. Celiac disease. N Engl J Med. 2012;367(25):2419–26.
https://doi.org/10.1056/NEJMcp1113994.
3. Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357(17):1731–43.
https://doi.org/10.1056/NEJMra071600.
4. Dehbozorgi M, Honar N, Eskandazadeh M, Saki F. Clinical manifestations
and associated disorders in children with celiac disease in southern Iran.
BMC Pediatr. 2020;20(1):1–7.
5. Dehghani SM, Haghighat M, Mobayan A, Rezaianzadeh A, Geramizadeh B.
Prevalence of celiac disease in healthy Iranian school children. Ann Saudi
Med. 2013;33(2):159–61. https://doi.org/10.1016/j.amssec.2013.159.
6. Seyhan MS, Atabek C, Aydilek B, Canpolat S, Ergun I, Kiziltasel N, Oner F, Ozdogan
M, Saglik A, Saraclar A, Seli L, Tuncay A, Yetkiner R, Aysel A, Mutlu FB, Cumingh H, Cicek
C, Erbas K, Elmas H, Sasmaz T, Tuncay F, Yilmaz P, Aysel S, Acar R, Erol E, Selcuk N, Ozdogan
M, Saglik A, Saraclar A, Seli L, Tuncay A, Yetkiner R, Aysel A, Acar R, Selcuk N. Prevalence
of celiac disease among Turkish children in the northwestern Marmara area.
BMC Pediatr. 2013;13:42. https://doi.org/10.1186/1471-2431-13-42.
7. Green PH, Wang YS, Ringler M, Collin P, Huxtable R, Celermajer D, Rowland T, Ledford
J, Walker-Smith JA, Greenberg GH, et al. Prevalence of celiac disease among
schoolchildren in the United States. Pediatrics. 2005;115(1):161–6. https://doi.org/
10.1542/peds.2004-0750.
8. Dehbozorgi M, Honar N, Eskandazadeh M, Saki F. Clinical manifestations
and associated disorders in children with celiac disease in southern Iran.
BMC Pediatr. 2020;20(1):1–7.
9. Seitz HK, Horak H, Sczepanska J, Proctor R, Johnson CE, Huxtable R, Wild G, yon
Hagen J, Cowan L, Royal A, et al. Prevalence and clinical features of gluten
sensitivity in a southern Ontario first- and second-degree family.
J Pediatr Gastroenterol Nutr. 2006;42(6):687–92. https://doi.org/10.1097/01.
GPG.0b013e3181b718a8.
6. Nejad MR, Rostami K, Emami MH, Zali MR, Malekzadeh R. Epidemiology of celiac disease in Iran: a review. Middle East J Dig Dis. 2011;3(1):5.

7. Halfdanarson TR, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. Blood. 2007;109(2):412–21. https://doi.org/10.1182/blood-2006-07-331104.

8. Akman S, Şahaboglu Ö, Daikan C, Bahteceler NN, Arıkan Ç. Is celiac disease misdiagnosed in children with functional constipation? Turk J Gastroenterol. 2018;29(2):210–4. https://doi.org/10.5152/tjg.2018.17369.

9. Jabari M. Use of Growth Hormone Therapy in Patients with Celiac Disease. An Overview. Life Sci J. 2016;13(9):41–7.

10. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, et al. Celiac disease: a comprehensive current review. BMJ Med. 2019;17(1):1–20.

11. Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PH, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62(1):43–52. https://doi.org/10.1136/gutjnl-2011-301346.

12. Oliveira GN, Mohan R, Fagbemi A. Review of celiac disease presentation in a pediatric tertiary centre. Arq Gastroenterol. 2018;55(1):86–93. https://doi.org/10.1590/0004-2803-201800000-17.

13. Barker JM, Liu E. Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions. Adv Pediatr. 2008;55(1):349–65. https://doi.org/10.1016/j.aped.2008.07.001.

14. Caprio E, Addolorato G, Mingrone G, De Gaetano A, Grocco AV, Tatarnini PA, et al. Changes in body composition, substrate oxidation, and resting metabolic rate in adult celiac disease patients after a 1-y gluten-free diet treatment. Am J Clin Nutr. 2000;72(2):71–86. https://doi.org/10.1093/ajcn/72.1.71.

15. Mezza C, Paganì S, Gettosio C, Bozzola E, Bozzola M. Celiac disease and short stature in children. Expert Rev Endocrinol Metab. 2014;9(5):535–42. https://doi.org/10.1586/17446651.2014.932248.

16. Yuan J, Gao J, Li L, Liu F, Wijmenga C, Chen H, et al. The tip of the “celiac iceberg” in China: a systematic review and meta-analysis. Plos One. 2013;8(12):e81151. https://doi.org/10.1371/journal.pone.0081151.

17. Catarci C, Fasanò A. Celiac disease as a cause of growth retardation in childhood. Curr Opin Pediatr. 2004;16(4):445–9. https://doi.org/10.1097/01.mop.0000133637.64414.20.

18. Assiri AMA. Isolated short stature as a presentation of celiac disease in Saudi children. Pediatr Rep. 2012;4(1):e415–7.

19. Ludvigsson JF, Rubio-Tapia A, Van Dyke CT, Melton LJ III, Zinsmeister AR, Littman AJ, et al. Mass screening for celiac disease among school-aged children: toward exploring celiac iceberg. J Pediatr Endocrinol Metab. 2020;33(8):995–1002.

20. Norris JM, Barriga K, Hoffenberg EJ, Taki I, Miao D, Haas JE, et al. Risk of celiac disease in short-statured children with no gastrointestinal symptoms. JAMA. 2005;293(19):2343. https://doi.org/10.1001/jama.293.19.2343.

21. Dehghani SM, Ostovar S, Ataollahi M, Javaherizadeh H. The effect of gluten-free diet treatment. Am J Clin Nutr. 2000;72(1):76. https://doi.org/10.1093/ajcn/72.1.76.

22. Calcaterra V, Regubbo C, Manuelli M, Klersy C, Pelizzo G, Albertini R, et al. Screening for celiac disease among children with overweight and obesity toward exploring celiac iceberg. J Pediatr Endocrinol Metab. 2020;33(8):995–1002.

23. Jabari M. Use of Growth Hormone Therapy in Patients with Celiac Disease. An Overview. Life Sci J. 2016;13(9):41–7.

24. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, et al. Celiac disease: a comprehensive current review. BMJ Med. 2019;17(1):1–20.

25. Barera G, Mora S, Brambilla P, Ricotti A, Menni L, Beccio S, et al. Body composition in children with celiac disease and the effects of a gluten-free diet: a prospective case-control study. Am J Clin Nutr. 2000;72(2):71–5. https://doi.org/10.1093/ajcn/72.2.71.

26. Cornean RE, Gheban D, Simionescu B, Margescu M. Celiac disease among children hospital, Faisalabad. Ann Punjab Med Coll. 2020;14(1):9–12.

27. Tümer L, Hasanoglu A, Aybav C. Endomysium antibodies in the diagnosis of celiac disease in short-statured children with no gastrointestinal symptoms. Pediatr Int. 2001;43(5):713–3. https://doi.org/10.1111/j.1442-200X.2001.01327.x.

28. Giovaneli D, Mezza C, Cardinale GM, Sposito M, Mastrangelo C, Messini B, et al. The prevalence of growth hormone deficiency and celiac disease in short children. Clin Wend Med. 2006;3(4):180–3. https://doi.org/10.3121/crmd.4.3.180.

29. Masood J, Rehman H, Anjum ZM, Jibbal I, Zafar S, Ayesha H. Prevalence of celiac disease in idiopathic short stature children presenting in OPD of children hospital, Faisalabad. Ann Punjab Med Coll. 2020;14(9):19–12.

30. Farooq A, Sheikh TK, Bashir H, Haroon S. Celiac Disease in children and the impact of late diagnosis. Methodol. 2020;12(3):136–40.

31. Parada AC, Mendez C, Aguirre C. Excess weight and gastrointestinal symptoms in Chilean celiac patients at the time of diagnosis. Rev Esp Enferm Dig. 2019;111(5):384–8.

32. Costa A, Brito GA. Anthropometric parameters in celiac disease: a review on the different evaluation methods and disease effects. J Nutr Metab. 2019; 2019:1–9. https://doi.org/10.1155/2019/4586963.

33. Barera G, Mora S, Brambilla P, Ricotti A, Menni L, Beccio S, et al. Body composition in children with celiac disease and the effects of a gluten-free diet: a prospective case-control study. Am J Clin Nutr. 2000;72(2):71–5. https://doi.org/10.1093/ajcn/72.2.71.

34. Calcaterra V, Regubbo C, Manuelli M, Klersy C, Pelizzo G, Albertini R, et al. Screening for celiac disease among children with overweight and obesity toward exploring celiac iceberg. J Pediatr Endocrinol Metab. 2020;33(8):995–1002.

35. Barera G, Mora S, Brambilla P, Ricotti A, Menni L, Beccio S, et al. Body composition in children with celiac disease and the effects of a gluten-free diet: a prospective case-control study. Am J Clin Nutr. 2000;72(2):71–5. https://doi.org/10.1093/ajcn/72.2.71.

36. The WHO Child growth standards. Available from: https://www.who.int/ growthcharts/en/. Accessed 8 Nov 2020.

37. Mezza C, Paganì S, Gettosio C, Bozzola E, Bozzola M. Celiac disease and short stature in children. Expert Rev Endocrinol Metab. 2014;9(5):535–42. https://doi.org/10.1586/17446651.2014.932248.

38. Yuan J, Gao J, Li L, Liu F, Wijmenga C, Chen H, et al. The tip of the “celiac iceberg” in China: a systematic review and meta-analysis. Plos One. 2013;8(12):e81151. https://doi.org/10.1371/journal.pone.0081151.

39. El-Refaey M, Atef M, El-Refaey M, El-Refaey M. Prevalence of thyroid disorders in untreated adult celiac disease patients and effect of gluten withdrawal: an Italian multicenter study. Am J Gastroenterol. 2001;96(3):751–7. https://doi.org/10.1111/j.1572-0241.2001.03617.x.
51. Ch’ng CL, Jones MK, Kingham JG. Celiac disease and autoimmune thyroid disease. Clin Med Res. 2007;5(3):184–92. https://doi.org/10.3121/cmrr.2007.738.

52. Dahlbom I, Korponay-Szabó IR, Kovács JB, Szabai Z, Mäki M, Hansson T. Prediction of clinical and mucosal severity of coeliac disease and dermatitis herpetiformis by quantification of IgA/IgG serum antibodies to tissue transglutaminase. J Pediatr Gastroenterol Nutr. 2010;50(2):140–6. https://doi.org/10.1097/MPG.0b013e3181a81384.

53. Alessio MG, Tonutti E, Brusca I, Licini L, Sonzogni A, et al. Correlation between IgA tissue transglutaminase antibody ratio and histological finding in celiac disease. J Pediatr Gastroenterol Nutr. 2012;55(1):44–9. https://doi.org/10.1097/MPG.0b013e3182470249.

54. Mubarak A, Wolters VM, Gmelig-Meyling FH, ten Kate FJ, Houwen RH. Tissue transglutaminase levels above 100 U/mL and celiac disease: a prospective study. World J Gastroenterol: WJG. 2012;18(32):4399. https://doi.org/10.3748/wjg.v18.i32.4399.

55. Singh P, Kurray L, Agnihotri A, Das P, Verma AK, Sreenivas V, et al. Titers of anti-tissue transglutaminase antibody correlate well with severity of villous abnormalities in celiac disease. J Clin Gastroenterol. 2015;49(3):212–7. https://doi.org/10.1097/MCG.0000000000000105.

56. Tiliberti C, Montuori M, Panimolle F, Trovato CM, Anania C, Valtutti F, et al. Screening for type 1 diabetes-, thyroid-, gastric-, and adrenal-specific humoral autoimmunity in 529 children and adolescents with celiac disease at diagnosis identifies as positive one in every nine patients. Diabetes Care. 2017;40(2):e1–e10. https://doi.org/10.2337/dc16-2095.

57. Ventura A, Magazzù G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. Gastroenterology. 1999;117(2):297–303. https://doi.org/10.1053/gast.1999.0029900297.

58. Tiliberti C, Montuori M, Trovato CM, Panimolle F, Filardi T, Valtutti F, et al. Gluten-free diet impact on dynamics of pancreatic islet-specific autoimmunity detected at celiac disease diagnosis. Pediatr Diabetes. 2020;21(5):774–80. https://doi.org/10.1111/pedi.13054.

59. Seyhan M, Erdem T, Ertelin V, Selimoğlu MA. The mucocutaneous manifestations associated with celiac disease in childhood and adolescence. Pediatr Dermatol. 2007;24(1):28–33. https://doi.org/10.1111/j.1525-1470.2007.00328.x.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.